Tag - merck

 
Menu
Search
 
April 19, 2024
 

Today's print edition

Home Delivery
Subscribe for more access

MERCK

Daiichi Sankyo is aiming for at least ¥900 billion of revenue from its oncology business in the fiscal year ending in March 2026.
BUSINESS
Oct 20, 2023
Merck signs $5.5 billion deal with Daiichi for cancer therapy development
Daiichi Sankyo is aiming for at least ¥900 billion of revenue from its oncology business in the fiscal year ending in March 2026.
Japan Times
WORLD / Science & Health
Jun 6, 2023
Cancer vaccines poised to unlock 'new treatment paradigm' with Merck-Moderna data
Scientists have been chasing the dream of vaccines to treat cancer for decades with few successes.
Japan Times
WORLD / Science & Health
Apr 17, 2023
Moderna-Merck cancer vaccine plus Keytruda delays recurrence of skin cancer
The findings of the recent trial suggest that adding a personalized cancer vaccine to antibody-based immunotherapy could prolong the time patients have without death or the cancer's return.
Japan Times
COMMENTARY / World
Jan 4, 2023
Cancer vaccine hunt finally makes progress
A small study shows promise in deploying mRNA technology against melanoma — but fighting tumors is vastly more complex than tackling COVID-19.
Japan Times
BUSINESS
Mar 15, 2022
Drugmakers pause trials in Russia while still sending medicine
Major pharmaceutical firms are seeking to strike a balance between international opprobrium over Russia's invasion of Ukraine and the needs of sick patients.
Japan Times
WORLD / Science & Health
Feb 1, 2022
How does Merck's COVID-19 pill compare to Pfizer's?
Pfizer said final trial results showed that its treatment reduced the chance of hospitalization or death by 89%, while Merck said their pill reduced those chances by 30%.
Japan Times
WORLD / Science & Health
Dec 24, 2021
Merck’s COVID-19 pill comes with warning for pregnant women
U.S. regulators cleared the drug for emergency use Thursday but said it is not recommended for use in pregnant people.
Japan Times
BUSINESS
Dec 17, 2021
Pfizer will dominate $20 billion COVID-19 pill market in 2022, analysis shows
Demand for the medications is poised to outpace supply as COVID-19 spreads around the globe and scientists question how well vaccines and antibody treatments will hold up against omicron.
Japan Times
WORLD
Nov 27, 2021
Merck says its antiviral pill is less effective in final analysis
A final analysis of a clinical trial said the antiviral pill reduced the risk of hospitalization and death among high-risk COVID patients by 30%, down from an earlier estimate of 50%.
Japan Times
JAPAN / Science & Health
Nov 10, 2021
Japan to pay $1.2 billion for 1.6 million courses of Merck's COVID-19 pill
Countries have rushed to sign deals to buy molnupiravir since data last month showed that when given early in the illness the drug could halve the chances of dying or being hospitalized.
Japan Times
COMMENTARY / World
Nov 7, 2021
COVID-19 drugs will change the way we live with the virus
New COVID-19 drug approvals couldn't be timelier as hospitals face massive backlogs of delayed procedures.
Japan Times
JAPAN / Explainer
Oct 20, 2021
Oral drug molnupiravir seen as 'trump card' in Japan's battle against COVID-19
The treatment developed by Merck could receive fast-track approval by the end of the year, and other oral drugs to fight the coronavirus are not far behind.
Japan Times
WORLD
Oct 14, 2021
Rush to buy Merck’s COVID-19 pill risks leaving poor countries behind
Despite efforts to license molnupiravir to generic-drug firms, the same risks of unequal distribution remain, says report.
Japan Times
JAPAN
Oct 4, 2021
Japan in talks to procure Merck oral drug for mild COVID-19 symptoms
Molnupiravir was seen to halve the likelihood of hospitalization or death, according to an interim analysis of clinical trials across areas including Japan, Europe and the U.S.
Japan Times
WORLD / Science & Health
Oct 2, 2021
Merck pill seen as 'huge advance,' raises hope of preventing COVID-19 deaths
An experimental antiviral pill developed by Merck & Co. could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19.
Japan Times
BUSINESS / FOCUS
Jun 4, 2021
Chinese drugmakers take aim at lucrative U.S. anti-cancer market
In recent years, medicines that free the immune system to attack tumors have become blockbusters in a $150 billion global market.
Japan Times
WORLD / Science & Health
Jul 23, 2019
Congo health minister's resignation over Ebola snub could unblock new vaccine
Congo's health minister resigned on Monday after being stripped of responsibility for managing the country's Ebola outbreak, potentially paving the way for the introduction of a second vaccine to contain the spreading epidemic.
Japan Times
WORLD / Science & Health
Aug 6, 2018
Experimental Ebola vaccinations to begin Wednesday in eastern Congo
Vaccinations against a new outbreak of Ebola virus in eastern Democratic Republic of Congo are due to begin on Wednesday, a senior official at the health ministry said on Sunday.
BUSINESS / Companies
Mar 8, 2018
Japan's Eisai agrees with U.S.-based Merck on potential $5.76 billion cancer drugs deal
Eisai Co. and U.S.-based Merck & Co. said Thursday they have agreed to jointly develop cancer drugs for global sales, with the Japanese pharmaceutical firm potentially receiving up to $5.76 billion if it proves a success.
Japan Times
WORLD
Aug 15, 2017
After Merck chief quits, Under Armour CEO steps down from Trump's business council
Under Armour Inc.'s Kevin Plank became the latest chief executive to quit President Donald Trump's council of U.S. business leaders, as membership on the panel has become enmeshed in the country's volatile politics after violent riots in Virginia over the weekend.
No link to Nankai Trough quake seen after temblor in Shikoku
Satoshi Harada from the Meteorological Agency explains about the magnitude 6.6 earthquake during a news conference early Thursday.
Thousands evacuated as Indonesia volcano erupts
Indonesia's Mount Ruang spews hot lava and smoke as seen from Sitaro, North Sulawesi, on Wednesday.
Why hasn't Japan moved to prop up the weak yen?
Finance Minister Shunichi Suzuki speaks to reporters in Tokyo on Tuesday.
Snake on a train: Discovery of serpent delays Tokyo-Nagoya shinkansen
A Tokaido shinkansen. It is unclear whether the snake was venomous or how it ended up on the train, and there was no injury or panic among passengers.
In a first, Japan doctors sue Google over negative reviews on firm's map app
One of the lawyers representing a group of doctors suing Google told a news conference that the main purpose of the lawsuit is not to seek compensation but instead to raise awareness over various problems with the Google Maps system.
'House of the Owl' brings Hollywood values to Japanese TV
In the new Disney+ series “House of the Owl,” Min Tanaka (left) plays a powerful political fixer, or “kuromaku,” who has a troubled relationship with his adult children, particularly his idealistic son, played by Mackenyu.
Benefits and risks: AUKUS looks to take gamble on Japan
U.S. President Joe Biden, Australian Prime Minister Anthony Albanese and British leader Rishi Sunak deliver remarks on the AUKUS partnership, after a trilateral meeting, at Naval Base Point Loma in San Diego in March last year.
Kyoto’s demon night parade lives to haunt another day
In a Kyoto long past, the "hyakki yagyō" (100 demon night parade) haunted a sleepy corner of Kyoto. Now, one enterprising monster enthusiast has won a small batttle to keep the march alive.
U.S. deploys midrange missile system in Indo-Pacific for first time
A U.S. Army Mid-Range Capability (MRC) Launcher arrives as part of the capability’s first deployment into theater on Northern Luzon, Philippines, April 8.
Unpacking the chaotic by-election in a scandal-hit Tokyo district
People listen to a campaign speech in Tokyo's Koto Ward on Tuesday.

Podcast

From easily navigable train stations to the helpfulness of its municipal staff, Tokyo has earned high praise for its commitment to accessibility for disabled travelers.
[Rebroadcast] Japan is doing better on accessibility than you may think

Longform

Historically, kabuki was considered the entertainment of the merchant and peasant classes, a far cry from how it is regarded today.
For Japan's oldest kabuki theater, the show must go on
By Lance Henderstein

SUSTAINABLE JAPAN

Prize winner Maki Imoto catches light with glass
Prize winner Maki Imoto catches light with glass

SPECIAL SUPPLEMENTS note

Read more

SUPPLEMENTS BINDER